Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BARCODE 2: Carboplatin in mCRPC with DNA Repair Gene Mutations
NCT02955082Phase 2Active, not recruiting
- Sponsor
- The Institute of Cancer Research
- Start
- May 2017
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin in prostate cancer (PCa), sponsored by The Institute of Cancer Research. Primary endpoints: Radiographic Treatment Response at 9 weeks and Biochemical Treatment Response at 6 weeks. Started May 2017; status: active, not recruiting.
02
Drugs
carboplatin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02955082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955082.